3 news items
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
AUTL
2 Apr 24
of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
AUTL
14 Mar 24
release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
AUTL
12 Mar 24
contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act
- Prev
- 1
- Next